Alkermes Presented New Data Analysis on Healthcare Resource Use Among Veterans With Alcohol Dependence - Seite 2

Details of the poster presentation at RSA are as follows:

• Poster #240: Treatment Patterns and Healthcare Resource Use Among Patients with Alcohol Dependence who Initiated Extended-Release Naltrexone: An Analysis of Veterans Affairs Data, was presented Sunday, June 20.

Alkermes previously presented data from another retrospective, observational study using the same VHA database at the Association of Military Surgeons of the United States (AMSUS), The Society of Federal Health Professionals, Annual Meeting in December 2020. That study was one of the first studies to provide insights into the patient journey among veterans from alcohol dependence diagnosis to VIVITROL initiation and beyond. Patients studied had extensive health care use and carried a high burden of chronic disease, including hypertension (40.5 percent), chronic pain (10.8 percent), and diabetes (9.7 percent). In addition, a majority had diagnoses for mental health comorbidities, such as depression (74.1 percent), non-alcohol/opioid substance use disorder (66.3 percent), and post-traumatic stress syndrome (52.9 percent). Key findings included:

• Although 25 percent of patients initiated VIVITROL within 60 days of diagnosis, the average time from initial diagnosis to VIVITROL initiation was analogous to 13.6 months.
• While many of the patients studied (75.8 percent) received oral naltrexone prior to initiating VIVITROL, 22.0 percent initiated VIVITROL as first-line medication. Additionally, about half of the patients studied (46.6 percent) did not initiate other alcohol dependence medications during the study period following initiation of treatment with VIVITROL.

About Alcohol Dependence
Alcohol dependence is a chronic, relapsing disease that poses serious and potentially fatal health risks.¹ In 2017, it affected nearly 8 million people aged 12 and older in the U.S., with a significant burden on veterans.²

About VIVITROL
VIVITROL (naltrexone for extended-release injectable suspension) is a once-monthly medication for the treatment of alcohol dependence and for the prevention of relapse to opioid dependence, following opioid detoxification. Treatment with VIVITROL should be part of a comprehensive management program that includes psychosocial support. For more information, visit www.vivitrol.com.